AX PHARMACEUTICAL CORP- cetirizine hcl powder
AX Pharmaceutical Corp

Caution: For manufacturing, processing, or repacking. Use according to practitioner's prescription. Federal law prohibits dispensing without prescription.

Keep tightly closed at controlled room temperature.

AX Pharmaceutical Corp

Toll free: 1 866 305 0566

Cetirizine Hydrochloride, EP

Retest date: June 05, 2022

Original Reference: BCTDZ17008

NDC: 62157-568-01

Relabelled by: AX Pharmaceutical Corp

500g

CAS: 83881-52-1

Lot: D087-17F06SH

100 West Beaver Creek Road, Unit 12, Richmond Hill, ON Canada L4B 1H4 Fax: 416 852 1618

Harmful if swallowed. May cause drowsiness or dizziness.

Dispose of contents/container in accordance with local/regional/national/international regulations.

Do not breathe dust/ fume/ gas/ mist/ vapours/ spray, avoid release to the environment, wear protective gloves , Wear respiratory protection, immediately call a POISON CENTER or doctor/ physician.

Warning

AX PHARMACEUTICAL CORP

cetirizine hcl powder

Product Information			
Product Type	BULK INGREDIENT	**Item Code (Source)**	NDC:62157-568
Route of Administration	NOT APPLICABLE		

Active Ingredient/Active Moiety		
Ingredient Name	**Basis of Strength**	**Strength**
CETIRIZINE HYDROCHLORIDE (UNII: 64O047KTOA) (CETIRIZINE - UNII:YO7261ME24)	CETIRIZINE HYDROCHLORIDE	495 g in 500 g

Inactive Ingredients	
Ingredient Name	**Strength**
WATER (UNII: 059QF0KO0R)	

Product Characteristics			
Color	white	**Score**	
Shape		**Size**	
Flavor		**Imprint Code**	
Contains			

Packaging				
#	**Item Code**	**Package Description**	**Marketing Start Date**	**Marketing End Date**
1	NDC:62157-568-01	500 g in 1 JAR	04/27/2018	

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
bulk ingredient for animal drug compounding		04/27/2018	

Labeler - AX Pharmaceutical Corp (202924858)

Establishment

Name	Address	ID/FEI	Business Operations
AX Pharmaceutical Corp		202924858	repack(62157-568) , relabel(62157-568)

Revised: 4/2018 AX Pharmaceutical Corp